IL-12 based gene therapy in veterinary medicine

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Pavlin, Darja ^a   Cemazar, Maja ^b   Sersa, Gregor ^b   Tozon, Natasa ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Cats; Dogs; Electroporation; Gene therapy; Horses; Interferon ; Interleukin 12; Plasmid

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; GAMMA INTERFERON; INTERLEUKIN 12; PLACEBO; PLASMID DNA; RECOMBINANT INTERLEUKIN 12;

ANEMIA; ANIMAL VENEREAL TUMOR; ANTINEOPLASTIC ACTIVITY; BODY TEMPERATURE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCHEMOTHERAPY; ELECTROPORATION; FIBROSARCOMA; GASTROINTESTINAL TOXICITY; GENE DELIVERY SYSTEM; GENE GUN; GENE THERAPY; HEAD AND NECK TUMOR; HEART DISEASE; HISTIOCYTIC SARCOMA; HUMAN; HYPOALBUMINEMIA; HYPOGLYCEMIA; IMMUNOMODULATION; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MASTOCYTOMA; MELANOMA; METASTATIC MELANOMA; MORQUIO SYNDROME; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMATITIS; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; TUMOR REGRESSION; VETERINARY MEDICINE; VOMITING; WEAKNESS;

ANIMALS; ANIMALS, DOMESTIC; ELECTROPORATION; GENETIC THERAPY; INTERLEUKIN-12; VETERINARY MEDICINE;

EID: 84869225533     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-234     Document Type: Review

References (84)

1. Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit 2005, 11:110-121.
2. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. T-lymphocyte-directed gene therapy for ADA-SCID: initial trial results. Science 1995, 270:475-480.
3. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990, 323:570-578.
4. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348:255-256.
5. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metabol 2003, 80:148-158.
6. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S. The dog as a cancer model. Nat Biotechnol 2006, 24:1065-1066.
7. Casal M, Haskins M. Large animal models and gene therapy. Eur J Hum Genet 2006, 14:266-272.
8. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989, 170:827-845.
9. Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, Gately MK. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 1990, 87:6808-6812.
10. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991, 146:3074-3081.
11. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
12. Voest EE, Kenyon BE, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995, 87:581-586.
13. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007, 13:4677-4685.
14. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997, 3:409-417.
15. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90:2541-2548.
16. Choi KJ, Zhang SN, Choi IK, Kim JS, Yun CO. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Ther 2012, 19:711-723.
17. Malvicini M, Ingolotti M, Piccioni F, Garcia M, Bayo J, Atorrasagasti C, Alaniz L, Aquino JB, Espinoza JA, Gidekel M, Scharovsky OG, Matar P, Mazzolini G. Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Mol Oncol 2011, 5:242-255.
18. Xu Y, Hou J, Liu Z, Yu H, Sun W, Xiong J, Liao Z, Zhou F, Xie C, Zhou Y. Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma. J Transl Med 2011, 9:39.
19. Puisieux I, Odin L, Poujol D, Moingeon P, Tartaglia J, Cox W, Favrot M. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum Gene Ther 1998, 9:2481-2492.
20. Asselin-Paturel C, Lassau N, Guinebretière JM, Zhang J, Gay F, Bex F, Hallez S, Leclere J, Peronneau P, Mami-Chouaib F, Chouaib S. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography,". Gene Ther 1999, 6:606-615.
21. Schultz J, Pavlovic J, Strack B, Nawrath N, Moelling K. Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. Human Gene Ther 1999, 10:407-417.
22. Dietrich A, Becherer L, Brinckmann U, Hauss J, Liebert UG, Gütz A, Aust G. Particle-mediated cytokine gene therapy leads to antitumor and antimetastatic effects in mouse carcinoma models. Cancer Biother Radiopharm 2006, 21:333-341.
23. Heller R, Schultz J, Lucas ML, Jaroszeski MJ, Heller LC, Gilbert RA, Moelling K, Nicolau C. Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. DNA Cell Biol 2001, 20:21-26.
24. Hanna E, Zhang X, Woodlis J, Breau R, Suen J, Li S. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther 2001, 8:151-157.
25. Lohr F, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y, Zhao Y, Dewhirst MW, Yuan F, Li CY. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 2001, 61:3281-3284.
26. Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther 2002, 9:260-266.
27. Hüttinger C, Hirschberger J, Jahnke A, Köstlin R, Brill T, Plank C, Küchenhoff H, Krieger S, Schillinger U. Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial. J Gene Med 2008, 10:655-667.
28. Nande R, Di Benedetto A, Aimola P, De Carlo F, Carper M, Claudio CD, Denvir J, Valluri J, Duncan GC, Claudio PP. Targeting a newly established spontaneous feline fibrosarcoma cell line by gene transfer. PLoS One 2012, 7:e37743.
29. Vite CH, McGowan JC, Niogi SN, Passini MA, Drobatz KJ, Haskins ME, Wolfe JH. Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol 2005, 57:355-364.
30. Fyfe JC, Kurzhals RL, Lassaline ME, Henthorn PS, Alur PR, Wang P, Wolfe JH, Giger U, Haskins ME, Patterson DF, Sun H, Jain S, Yuhki N. Molecular basis of feline beta-glucuronidase deficiency: an animal model of mucopolysaccharidosis VII. Genomics 1999, 58:121-128.
31. Ellinwood NM, Vite CH, Haskins ME. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 2004, 6:481-506.
32. Sleeper M, Bish LT, Haskins M, Ponder KP, Sweeney HL. Status of therapeutic gene transfer to treat cardiovascular disease in dogs and cats. J Vet Cardiol 2011, 13:131-140.
33. Siddiqui F, Li CY, Larue SM, Poulson JM, Avery PR, Pruitt AF, Zhang X, Ullrich RL, Thrall DE, Dewhirst MW, Hauck ML. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol Cancer Ther 2007, 6:380-389.
34. Kirpensteijn J. Feline injection site-associated sarcoma: Is it a reason to critically evaluate our vaccination policies?. Vet Microbiol 2006, 117:59-65.
35. Davidson EB, Gregory CR, Kass PH. Surgical excision of soft tissue fibrosarcomas in cats. Vet Surg 1997, 26:265-269.
36. Hershey AE, Sorenmo KU, Hendrick MJ, Shofer FS, Vail DM. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). J Am Vet Med Assoc 2000, 216:58-61.
37. Jahnke A, Hirschberger J, Fischer C, Brill T, Köstlin R, Plank C, Küchenhoff H, Krieger S, Kamenica K, Schillinger U. Intra-tumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study. J Vet Med A Physiol Pathol Clin Med 2007, 54:599-606.
38. Quintin-Colonna F, Devauchelle P, Fradelizi D, Mourot B, Faure T, Kourilsky P, Roth C, Mehtali M. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther 1996, 3:1104-1112.
39. Jourdier TM, Moste C, Bonnet MC, Delisle F, Tafani JP, Devauchelle P, Tartaglia J, Moingeon P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 2003, 10:2126-2132.
40. Marini FC, Cannon JP, Belmont JW, Shillitoe EJ, Lapeyre JN. In vivo marking of spontaneous or vaccine-induced fibrosarcomas in the domestic house cat, using an adenoviral vector containing a bifunctional fusion protein, GAL-TEK. Human Gene Ther 1995, 6:1215-1223.
41. Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, Woerly G, Huang S, Aguet M, Anderson TD, Ryffel B. Role of interferon-gamma in interleukin 12-induced pathology in mice. Am J Pathol 1995, 147:1693-1707.
42. Seltenhammer MH, Heere-Ress E, Brandt S, Druml T, Jansen B, Pehamberger H, Niebauer GW. Comparative histopathology of grey-horse-melanoma and human malignant melanoma. Pigment Cell Res 2004, 17:674-681.
43. Rieder S, Stricker C, Joerg H, Dummer R, Stranzinger G. A comparative genetic approach for the investigation of ageing grey horse melanoma. J Anim Breeding Genetics 2000, 117:73-82.
44. MacGillivray KC, Sweeney RW, Del Piero F. Metastatic melanoma in horses. J Vet Intern Med 2002, 16:452-456.
45. Finocchiaro LM, Riveros MD, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as adjuvant treatments of metastatic melanoma in a horse. Vet Rec 2009, 164:278-227.
46. Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G, Moelling K. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med (Berl) 2001, 78:692-702.
47. Müller JM, Wissemann J, Meli ML, Dasen G, Lutz H, Heinzerling L, Feige K. In vivo induction of interferon gamma expression in grey horses with metastatic melanoma resulting from direct injection of plasmid DNA coding for equine interleukin 12. Schweiz Arch Tierheilkd 2011, 153:509-513.
48. Müller J, Feige K, Wunderlin P, Hödl A, Meli ML, Seltenhammer M, Grest P, Nicolson L, Schelling C, Heinzerling LM. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother 2011, 34:58-64.
49. Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, Pavlovic J, Moelling K. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005, 16:35-48.
50. Felsburg PJ, Somberg RL, Hartnett BJ, Henthorn PS, Carding SR. Canine X-linked severe combined immunodeficiency. A model for investigating the requirement for the common gamma chain (gamma c) in human lymphocyte development and function. Immunol Res 1998, 17:63-73.
51. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, DeJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438:803-819.
52. Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG, Getzy DM, Duke RC, Withrow SJ, Lana S, Matthiesen DT, Dow SW, Bellgrau D, Cutter GR, Helfand SC, Modiano JF. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther 2003, 10:726-736.
53. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998, 101:2406-2414.
54. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Yang NS, MacEwen EG. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther 1999, 6:26-36.
55. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS, MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Human Gene Ther 1998, 9:1851-1861.
56. Thamm DH, Kurzman ID, Macewen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT. Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother 2003, 52:473-480.
57. Pavlin D, Cemazar M, Cör A, Sersa G, Pogacnik A, Tozon N. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol 2011, 45:31-39.
58. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther 2010, 17:457-464.
59. Draghia-Akli R, Hahn KA, King GK, Cummings KK, Carpenter RH. Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol Ther 2002, 6:830-836.
60. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982, 1:841-845.
61. Wolff JA, Malone RW, Williams P. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:465-1468.
62. Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1991, 1088:131-134.
63. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006, 6:243-273.
64. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010, 10:300-311.
65. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008, 26:5896-5903.
66. Cemazar M, Sersa G, Pavlin D, Tozon N. Intramuscular IL-12 Electrogene Therapy for Treatment of Spontaneous Canine Tumors. Targets in gene therapy 2011, 299-320. Rijeka, Croatia.
67. Chuang TF, Lee SC, Liao KW, Hsiao YW, Lo CH, Chiang BL, Lin XZ, Tao MH, Chu RM. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer 2009, 125:698-707.
68. Buettner M, Belke-Louis G, Rziha HJ, McInnes C, Kaaden OR. Detection, cDNA cloning and sequencing of canine interleukin 12. Cytokine 1998, 10:241-248.
69. Phillips BS, Padilla ML, Dickerson EB, Lindstrom MJ, Helfand SC. Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs. Vet Immunol Immunopathol 1999, 70:189-201.
70. Hsiao YW, Liao KW, Hung SW, Chu RM. Effect of tumor infiltrating lymphocytes on the expression of HMC molecules in canine transmissible venereal tumors (TVT) in dogs. Oncogene 2002, 1:399-406.
71. Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogacnik A, Sersa G. Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther 2009, 8:2114-2122.
72. Li S, Zhang L, Torrero M, Cannon M, Barret R. Administration route- and immune cell activation-dependant tumor eradication by IL-12 electrotransfer. Mol Ther 2005, 12:942-949.
73. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002, 5:668-675.
74. Heinzerling L, Dummer R, Ravlivic J, Schulth J, Burg G, Moelling K. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. Exp Dermatol 2002, 11:232-240.
75. Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 2008, 423:319-325.
76. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs 2000, 11:201-208.
77. Cemazar M, Sersa G, Miklavcic D. Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin. Anticancer Res 1998, 18:4463-4466.
78. Lucas ML, Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 2003, 22:755-763.
79. Pavlin D, Tozon N, Sersa G, Pogacnik A, Cemazar M. Efficient electrotransfectionline into canine muscle. Technol Cancer Res Treat 2008, 7:45-54.
80. Tevz G, Pavlin D, Kamensek U, Kranjc S, Mesojednik S, Coer A, Sersa G, Cemazar M. Gene electrotransfer into murine skeletal muscle: a systematic analysis of parameters for long-term gene expression. Technol Cancer Res Treat 2008, 7:91-101.
81. Rassnick KM, Moore AS, Russel DS, Northrup NC, Kristal O, Bailey DB, Flory AB, Kiselow MA, Intile JL. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. J Vet Intern Med 2010, 24:1528-1531.
82. Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS, LeBlanc AK, Sabhlok A, Mauldin EA, Shofer FS, Couto CG, Sørenmo KU. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med 2007, 21:121-126.
83. Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud A, Heller R. Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clin Cancer Res 2006, 12:3177-3183.
84. Reed SD, Li S. Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy. Cancer Gene Ther 2011, 18:265-274.